Format
Items per page
Sort by

Send to:

Choose Destination

Results: 1 to 20 of 282

Similar articles for PubMed (Select 1873774)

1.

A phase II trial of high-dose cisplatin and dacarbazine. Lack of efficacy of high-dose, cisplatin-based therapy for metastatic melanoma.

Steffens TA, Bajorin DF, Chapman PB, Lovett DR, Cody-Johnson BV, Templeton MA, Heelan RT, Wong GY, Portlock CS, Oettgen HF, et al.

Cancer. 1991 Sep 15;68(6):1230-7.

PMID:
1873774
2.
3.

High-dose cisplatin plus dacarbazine in the treatment of metastatic melanoma.

Murren JR, DeRosa W, Durivage HJ, Davis C, Makuch R, Portlock CS.

Cancer. 1991 Mar 15;67(6):1514-7.

PMID:
2001539
4.

A phase II pilot trial of concurrent biochemotherapy with cisplatin, vinblastine, dacarbazine, interleukin 2, and interferon alpha-2B in patients with metastatic melanoma.

McDermott DF, Mier JW, Lawrence DP, van den Brink MR, Clancy MA, Rubin KM, Atkins MB.

Clin Cancer Res. 2000 Jun;6(6):2201-8.

5.
6.

Temozolomide and interferon alpha 2b in metastatic melanoma stage IV.

Richtig E, Hofmann-Wellenhof R, Pehamberger H, Forstinger Ch, Wolff K, Mischer P, Raml J, Fritsch P, Zelger B, Ratzinger G, Koller J, Lang A, Konrad K, Kindermann-Glebowski E, Seeber A, Steiner A, Fialla R, Pachinger W, Kos C, Klein G, Kehrer H, Kerl H, Ulmer H, Smolle J.

Br J Dermatol. 2004 Jul;151(1):91-8.

PMID:
15270876
7.

Multiinstitutional phase II trial of intensive combination chemoimmunotherapy for metastatic melanoma.

Atkins MB, O'Boyle KR, Sosman JA, Weiss GR, Margolin KA, Ernest ML, Kappler K, Mier JW, Sparano JA, Fisher RI, et al.

J Clin Oncol. 1994 Aug;12(8):1553-60.

PMID:
8040667
8.

Comparison of the efficacy of two different dosage dacarbazine-based regimens and two regimens without dacarbazine in metastatic melanoma: a single-centre randomized four-arm study.

Jelić S, Babovic N, Kovcin V, Milicevic N, Milanovic N, Popov I, Radosavljevic D.

Melanoma Res. 2002 Feb;12(1):91-8.

PMID:
11828263
9.

Phase II trial of dacarbazine and thalidomide for the treatment of metastatic melanoma.

Ott PA, Chang JL, Oratz R, Jones A, Farrell K, Muggia F, Pavlick AC.

Chemotherapy. 2009;55(4):221-7. doi: 10.1159/000219435. Epub 2009 May 19.

PMID:
19451711
10.

High-dose cisplatin with dacarbazine and tamoxifen in the treatment of metastatic melanoma.

Buzaid AC, Murren JR, Durivage HJ.

Cancer. 1991 Sep 15;68(6):1238-41.

PMID:
1873775
11.
12.

Phase II multicenter trial of maintenance biotherapy after induction concurrent Biochemotherapy for patients with metastatic melanoma.

O'Day SJ, Atkins MB, Boasberg P, Wang HJ, Thompson JA, Anderson CM, Gonzalez R, Lutzky J, Amatruda T, Hersh EM, Weber JS.

J Clin Oncol. 2009 Dec 20;27(36):6207-12. doi: 10.1200/JCO.2008.20.3075. Epub 2009 Nov 16.

13.

High-dose cisplatin plus WR-2721 in a split course in metastatic malignant melanoma. A phase II study.

Buzaid AC, Murren J, Durivage HJ.

Am J Clin Oncol. 1991 Jun;14(3):203-7.

PMID:
1851602
14.

Sequential dacarbazine chemotherapy followed by recombinant interleukin-2 in metastatic melanoma. A pilot multicentre phase I-II study.

Shiloni E, Pouillart P, Janssens J, Splinter T, Di Peri T, Symann M, Roest GJ, Palmer PA, Franks CR.

Eur J Cancer Clin Oncol. 1989;25 Suppl 3:S45-9.

PMID:
2697579
15.

Randomized, double-blind, placebo-controlled trial comparing the response rates of carmustine, dacarbazine, and cisplatin with and without tamoxifen in patients with metastatic melanoma. National Cancer Institute of Canada Clinical Trials Group.

Rusthoven JJ, Quirt IC, Iscoe NA, McCulloch PB, James KW, Lohmann RC, Jensen J, Burdette-Radoux S, Bodurtha AJ, Silver HK, Verma S, Armitage GR, Zee B, Bennett K.

J Clin Oncol. 1996 Jul;14(7):2083-90.

PMID:
8683240
16.

Phase II multicentre study of temozolomide in combination with interferon alpha-2b in metastatic malignant melanoma.

García M, del Muro XG, Tres A, Crespo C, Valladares M, López JJ, Rifà J, Pérez X, Filipovich E, Germà-Lluch JR.

Melanoma Res. 2006 Aug;16(4):365-70.

PMID:
16845333
17.

A phase II study of neoadjuvant biochemotherapy for stage III melanoma.

Gibbs P, Anderson C, Pearlman N, LaClaire S, Becker M, Gatlin K, O'Driscoll M, Stephens J, Gonzalez R.

Cancer. 2002 Jan 15;94(2):470-6.

PMID:
11900232
18.

Dacarbazine, cisplatin, and interferon-alfa-2b with or without interleukin-2 in metastatic melanoma: a randomized phase III trial (18951) of the European Organisation for Research and Treatment of Cancer Melanoma Group.

Keilholz U, Punt CJ, Gore M, Kruit W, Patel P, Lienard D, Thomas J, Proebstle TM, Schmittel A, Schadendorf D, Velu T, Negrier S, Kleeberg U, Lehman F, Suciu S, Eggermont AM.

J Clin Oncol. 2005 Sep 20;23(27):6747-55.

19.
20.

A phase II study of dacarbazine and cisplatin in combination with outpatient administered interleukin-2 in metastatic malignant melanoma.

Flaherty LE, Robinson W, Redman BG, Gonzalez R, Martino S, Kraut M, Valdivieso M, Rudolph AR.

Cancer. 1993 Jun 1;71(11):3520-5.

PMID:
8490900
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Write to the Help Desk